Factor IX replacement in surgery and prophylaxis.

Anaadriana Zakarija*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Considerations for treatment of hemophilia B patients in high-risk settings are the focus of this paper, including differences in recoveries of factor IX products and variable patient responses to replacement therapy. Data support the importance of performing individual pharmacokinetic studies in determining treatment programs for hemophilia patients-for both high-risk periods such as surgery and for prophylaxis. Other considerations in choice of plasma-derived or recombinant factor IX concentrate in high-risk and other situations include product safety, cost, and availability.

Original languageEnglish (US)
JournalBlood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
Volume15 Suppl 2
StatePublished - Jan 1 2004

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Factor IX replacement in surgery and prophylaxis.'. Together they form a unique fingerprint.

Cite this